Improvement in Bone Properties by Using Risedronate Adsorbed Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of Osteoporosis

Sahana, H; Dk, Khajuria; Razdan, Rema; Dr, Mahapatra; Mr, Bhat; Suresh, Snophia; Rr, Rao; Mariappan, Leo

doi:10.1166/jbn.2013.1482

Cited by 56 publications

(34 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the composition, size and physicochemical properties of the tested materials is significantly different in the published studies, [26][27][28][29][30][31][32][33][34][35][36][37][38] globally the results are promising, suggesting that the utilization of nanobiomaterials may represent a suitable alternative for the conventional and, at the present, most used microscaled biomaterials. However, more studies are needed in order to gather a detailed knowledge about the true potential applications of such materials.…”

Section: Discussionmentioning

confidence: 95%

Complex Effect of Hydroxyapatite Nanoparticles on the Differentiation and Functional Activity of Human Pre-Osteoclastic Cells

Costa‐Rodrigues¹,

Silva²,

Santos³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

Nanosized hydroxyapatite (HA) is a promising material in clinical applications targeting the bone tissue. NanoHA is able to modulate bone cellular events, which accounts for its potential utility, but also raises safety concerns regarding the maintenance of the bone homeostasis. This work analyses the effects of HA nanoparticles (HAnp) on osteoclastic differentiation and activity, an issue that has been barely addressed. Rod-like HAnp, produced by a hydrothermal precipitation method, were tested on peripheral blood mononuclear cells (PBMC), which contains the CD14+ osteoclastic precursors, in unstimulated or osteoclastogenic-induced conditions. HAnp were added at three time-points during the osteoclastic differentiation pathway, and cell response was evaluated for osteoclastic related parameters. Results showed that HAnp modulated the differentiation and function of osteoclastic cells in a dose-and time-dependent manner. In addition, the effects were dependent on the stage of osteoclastic differentiation. In unstimulated PBMC, HAnp significantly increased osteoclastogenesis, leading to the formation of mature osteoclasts, as evident by the significant increase of TRAP activity, number of TRAP-positive multinucleated cells, osteoclastic gene expression and resorbing ability. However, in a population of mature osteoclasts (formed in osteoclastogenic-induced PBMC cultures), HAnp caused a dose-dependent decrease on the osteoclastic-related parameters. These results highlight the complex effects of HAnp in osteoclastic differentiation and activity, and suggest the possibility of HAnp to modulate/disrupt osteoclastic behavior, with eventual imbalances in the bone metabolism. This should be carefully considered in bone-related and other established and prospective biomedical applications of HAnp.

show abstract

Section: Discussionmentioning

confidence: 95%

Complex Effect of Hydroxyapatite Nanoparticles on the Differentiation and Functional Activity of Human Pre-Osteoclastic Cells

Costa‐Rodrigues¹,

Silva²,

Santos³

et al. 2014

j biomed nanotechnol

View full text Add to dashboard Cite

show abstract

“…Despite their therapeutic effects, bisphosphonates are currently used in various studies as suitable targeting agents in radiotherapy [4,5] . Previous studies from our laboratory and others have shown that bisphosphonates could be useful as drug bone targeted carriers for delivering various nanoparticle-based therapeutic interventions to bone tissues for skeletal-related diseases [6][7][8][9][10] . This approach prevents adverse effects such as toxicity due to non-specific tissue interactions, larger medicine dosages, higher costs, and even likely poor patient compliance towards therapy.…”

Section: Research Papermentioning

confidence: 99%

Sensitive and Rapid RP-HPLC Quantification of Zoledronic Acid in a Hydroxyapatite-based Nanoparticles

Khajuria¹,

Razdan²

2017

pharmaceutical-sciences

Self Cite

View full text Add to dashboard Cite

The aim of this study was to develop and validate a rapid and sensitive reverse-phase high performance liquid chromatography method for the quantitative determination of zoledronic acid in nanoparticles. The mobile phase was a mixture of methanol (30%) and 7 mM tetra butyl ammonium hydrogen sulphate, 2 mM di-sodium hydrogen orthophosphate and sulphate and 8 mM di-potassium hydrogen orthophosphate (70%), pH adjusted to 3 with trifluoroacetic acid. C18 column was used as a stationary phase. The flow rate was maintained at 1 ml/min. The detection of the constituents was done at 215 nm using an ultraviolet detector. Method validation was executed according to the International Conference on Harmonisation guidelines. The retention time of zoledronic acid was 3.27±0.03 min (n=6). The assay was linear over the concentration range of 200-800 μg/ml. The proposed method was sensitive with the limit of detection and limit of quantification values equal to 200 and 800 µg/ml, respectively. The method was accurate with percent mean recovery from 99.01±1.31 to 100.80±0.094% and precise as percent relative standard deviation values were less than 1%. The method was successfully applied for the estimation of zoledronic acid loading efficiency on hydroxyapatite nanoparticles and in vitro zoledronic acid release profile analysis in hydroxyapatite-based nanoparticles.

show abstract

“…The results strongly advocate that the RIS-HA-loaded NPs, which is a novel nanoparticle-based formulation, has a therapeutic advantage over RIS monotherapy for the treatment of OP in a rat model of postmenopausal OP. It may be useful in future for the treatment of OP in human being (Sahana et al, 2013).…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Bisphosphonates: therapeutics potential and recent advances in drug delivery

et al. 2014

View full text Add to dashboard Cite

Context: Bisphosphonates (BPs) are widely used for prevention and treatment of osteoporosis. BPs are known as gold standard for osteoporosis (OP) treatment due to their positive results in clinical studies. But some serious side effects are associated with BPs like gastrointestinal adverse effect i.e. esophagitis and ulcer of esophagus. Oral bioavailability (BA) of BPs ranges from 0.6 to 1% due to poor absorption through gastrointestinal tract (GIT). Objective: The main objective of this review is to explore the role of novel drug delivery systems (DDSs) for the delivering of BPs and minimizing the drawbacks associated with them. Methods: The current review is focusing on classification, mechanism of action, and limitations of BPs, and is also dwelling on the use of novel DDSs like nanoparticles, liposomes, topical, transdermal systems, implants, bisphosphonate osteotropic DDS (BP-ODDS), microspheres, and calcium phosphate cements (CPCs) for BPs. This review also gives a critically reviewed compilation of the various in vitro and in vivo studies conducted till date. Conclusion: On the basis of the exhaustive literature, it has been found that the novel DDS minimizes the side effects associated with BPs and enhances the BA. The advance drug delivery has a greater impact on reducing the undesirable effects and increasing the BA of BPs.

show abstract

Improvement in Bone Properties by Using Risedronate Adsorbed Hydroxyapatite Novel Nanoparticle Based Formulation in a Rat Model of Osteoporosis

Cited by 56 publications

References 22 publications

Complex Effect of Hydroxyapatite Nanoparticles on the Differentiation and Functional Activity of Human Pre-Osteoclastic Cells

Complex Effect of Hydroxyapatite Nanoparticles on the Differentiation and Functional Activity of Human Pre-Osteoclastic Cells

Sensitive and Rapid RP-HPLC Quantification of Zoledronic Acid in a Hydroxyapatite-based Nanoparticles

Bisphosphonates: therapeutics potential and recent advances in drug delivery

Contact Info

Product

Resources

About